Media Coverage

Jump Starting the Non-Profit Research Engine


While the process of drug discovery remains constant, the groups driving the scientific innovation now include those typically associated with fund-raising, lobbying and patient advocacy. Along with biopharmaceutical companies, which have been at the helm of drug discovery for years and continue to be the dominant player, one finds an increasing number of not-for-profit disease foundations angling for a seat at the lab bench.

Advances in PCR Improve Health of Animal Research Colonies


Reducing the use of laboratory animals has been a long-term goal in biological research. Many in vivo assays, like rabbit endotoxin testing or mouse antibody production testing to detect viral contaminants have largely been replaced by in vitro enzyme or PCR-based assays.

James Foster Interview on Mad Money with Jim Cramer


Live from the JP Morgan Healthcare Conference, James Foster, chairman and CEO at Charles River Laboratories spoke with Mad Money on CNBC. James Foster and Jim Cramer discuss the company’s strategic focus on helping accelerate drug discovery and development.  

On the Hunt Against Huntington’s Disease


CHDI Foundation, Inc. has extended its ongoing collaboration with Charles River Laboratories for discovering novel drugs for Huntington's disease for an additional five years.

Development of a Viral Induction Study for Cell Bank Characterization


An approach to consider for detecting latent or endogenous viruses in cell substrates is the use of assays that employ specific chemical compounds to induce virus expression or replication. Following induction, latent and endogenous viruses can then be detected through subsequent assays, such as TEM and QF-PCR testing.

Ready, Aim, CRISPR (or RNAi)


When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.

Overcoming Cell Line Complacency


Don’t fall into the cell line misidentification trap. Authenticate! What you don’t know–or what you refuse to acknowledge–will hurt you.

Charles River's Early Drug Discovery Business and CHDI Foundation Extend Huntington's Disease Collaboration


Today, Charles River Laboratories announced that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington's disease. CHDI has expanded the collaboration with Charles River due to its neuroscience expertise and comprehensive integrated drug discovery capability.

Will Pharma Talent Help Transform CROs Into CSOs?


It's no secret that Big Pharma is shedding scientific talent, which is migrating to smaller biotech companies and CROs. As Big Pharma continues to shrink, they will rely even more on those two segments. With more scientific talent in those areas, it can be a win/win situation.

The Essential Elements of a Good Sponsor/CRO Relationship


The pharma/CRO relationship can be a complicated one. Each side knows what it wants to gain from the relationship, but those goals or the route to achieve them do not always align. Having a fundamental understanding of what the other side is hoping to accomplish is critical to the relationship developing and maturing in a productive and harmonious manner.

Displaying results 1-10 (of 51)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|